{"article_title": "Amag Pharma Acquires GTCR&#8217;s Cord Blood Registry", "article_keywords": ["cord", "firm", "amag", "pharma", "business", "partners", "blood", "gtcr8217s", "private", "registry", "gtcr", "software", "gtcrs", "acquires"], "article_url": "http://www.themiddlemarket.com/news/healthcare/amag-pharma-acquires-gtcrs-cord-blood-registry-257022-1.html", "article_text": "Amag Pharma Acquires GTCR\u2019s Cord Blood Registry\n\nThe exit follows the PE firm\u0092s purchase of pharmacy-management software Rx30\n\nAmag Pharmaceuticals Inc. (Nasdaq: AMAG) is buying GTCR\u0092s Cord Blood Registry for $700 million.\n\nHeadquartered in San Bruno, California, Cord Blood enables families to preserve blood cells and tissue from a baby\u0092s umbilical cord for the family\u0092s potential future medical use. The business also partners with institutions to establish U.S. Food & Drug Administration-regulated clinical trials for medical conditions that don\u0092t yet have cures.\n\nThe buyer, Amag, is a specialty pharmaceutical company headquartered in Waltham, Massachusetts. The business develops maternal health, anemia management and cancer care products.\n\nChicago private equity firm GTCR has backed Cord Blood since 2012, when it partnered with life sciences executive Geoffrey Crouse to buy the business. The deal was consistent with GTCR\u0092s the Leaders Strategy, under which the firm partners with industry experts to acquire and grow companies. The method won GTCR Mergers & Acquisitions M&A Mid-Market Private Equity Firm of the Year award for 2013. For the firm, the Cord Blood exit comes on the heels of an investment in pharmacy management software Rx30, announced earlier in June.\n\nKirkland & Ellis LLP provided legal counsel to GTCR and Cord Blood. Goodwin Proctor advised Amag on the transaction.\n\nIn another stem cell-related deal, Longitude Venture Partners II LP and NovaQuest Pharma Opportunities Fund III LP acquired California Cryobank Inc., which provides donor sperm and stem-cell services, in August.\n\nFor more information on related topics, visit the following:", "article_metadata": {"og": {"url": "http://www.themiddlemarket.com/news/healthcare/amag-pharma-acquires-gtcrs-cord-blood-registry-257022-1.html", "image": "http://cdn.themiddlemarket.com/media/newspics/stem-cell-research.jpg", "site_name": "Mergers & Acquisitions, Latest News", "title": "Amag Pharma Acquires GTCR\u2019s Cord Blood Registry"}}, "article_summary": "Amag Pharma Acquires GTCR\u2019s Cord Blood RegistryThe exit follows the PE firm\u0092s purchase of pharmacy-management software Rx30Amag Pharmaceuticals Inc. (Nasdaq: AMAG) is buying GTCR\u0092s Cord Blood Registry for $700 million.\nHeadquartered in San Bruno, California, Cord Blood enables families to preserve blood cells and tissue from a baby\u0092s umbilical cord for the family\u0092s potential future medical use.\nChicago private equity firm GTCR has backed Cord Blood since 2012, when it partnered with life sciences executive Geoffrey Crouse to buy the business.\nKirkland & Ellis LLP provided legal counsel to GTCR and Cord Blood.\nFor the firm, the Cord Blood exit comes on the heels of an investment in pharmacy management software Rx30, announced earlier in June."}